Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)

Blood

Volumn 106, Issue 6, 2005, Pages 2169-2174

  Farinha, Pedro ^b   Masoudi, Hamid ^b   Skinnider, Brian F ^b   Shumansky, Karey ^b   Spinelli, John J ^b   Gill, Karamjit ^b   Klasa, Richard ^b   Voss, Nicolas ^b   Connors, Joseph M ^b   Gascoyne, Randy D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; BLEOMYCIN; CD68 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; VINCRISTINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; LYMPHOMA ASSOCIATED MACROPHAGE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 24744438473     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2005-04-1565     Document Type: Article

References (40)

1. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909-3918.
2. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984;311:1471-1475.
3. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258-1265.
4. Federico M, Vitolo U, Zinzani PL, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases; Intergruppo Italiano Linfomi. Blood. 2000;95:783-789.
5. Hans CP, Weisenburger DD, Vose JM, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood. 2003;101:2363-2367.
6. Johnson A, Brun A, Dictor M, Rambech E, Akerman M, Anderson H. Incidence and prognostic significance of t(14;18) translocation in follicle center cell lymphoma of low and high grade: a report from southern Sweden. Ann Oncol. 1995;6: 789-794.
7. Lestou VS, Gascoyne RD, Sehn L, et al. Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. Br J Haematol. 2003;122:745-759,
8. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood. 1993;82:2289-2295.
9. Lopez-Guillermo A, Cabanillas F, McDonnell TI, et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood. 1999;93:3081-3087.
10. Louie DC, Hochauser D, Schluger A, et al. Bcl6 and bcl2 rearrangement and p53 over-expression as prognostic factors in follicular lymphoma. Ann Oncol. 1996;7:16.
11. Martinez-Climent JA, Alizadeh AA, Segraves R, et al. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood. 2003;101: 3109-3117.
12. Moller MB, Nielsen O, Pedersen NT. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma. Histopathology. 2002;41:322-330.
13. Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood. 1993;82:1994-2004.
14. Sehn L, Gascoyne RD, Connors JM, Klasa R, Horsman DE, Comparison of t(14;18)-positive and t(14;18)-negative follicular lymphoma: clinical characteristics, outcome and cytogenetics [abstract]. Blood. 2000;96:2467a.
15. Shiozawa E, Yamochi-Onizuka T, Yamochi T, et al. Disappearance of CD21-positive follicular dendritic cells preceding the transformation of follicular lymphoma: immunohistological study of the transformation using CD21, p53, Ki-67, and P-glycoprotein, Pathol Res Pract. 2003;199:293-302.
16. Viardot A, Moller P, Hogel J, et al. Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. J Clin Oncol. 2002;20:4523-4530.
17. Zhao WL, Daneshpouy ME, Mounier N, et al. Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood. 2004;103:695-697,
18. Yano T, Jaffe ES, Longo DL, Raffeld M. MYC rearrangements in histologically progressed follicular lymphomas. Blood. 1992;80:758-767.
19. Tilly H, Rossi A, Stamatoullas A, et al. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood. 1994;84:1043-1049.
20. Pinyol M, Cobo F, Bea S, et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood. 1998;91:2977-2984.
21. Matolcsy A, Warnke RA, Knowles DM. Somatic mutations of the translocated bcl-2 gene are associated with morphologic transformation of follicular lymphoma to diffuse large-cell lymphoma. Ann Oncol. 1997;8:119-122.
22. Koster A, van Krieken JH, Mackenzie MA, et al. Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res. 2005;11:154-161.
23. Hough RE, Goepel JR, Alcock HE, Hancock BW, Lorigan PC, Hammond DW. Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma. Br J Cancer. 2001;84:499-503.
24. Hoglund M, Sehn L, Connors JM, et al. Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer. 2004;39: 195-204.
25. Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabhai M, Jaffe ES, Raffeld M. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood. 1998;91:4677-4685.
26. Akasaka T, Lossos IS, Levy R. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood. 2003;102:1443-1448.
27. Bilalovic N, Blystad AK, Golouh R, et al. Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma. Am J Clin Pathol. 2004;121:34-42.
28. Nathwani BN, Anderson JR, Armitage JO, et al. Clinical significance of follicular lymphoma with monocytoid B cells: Non-Hodgkin's Lymphoma Classification Project. Hum Pathol. 1999;30:263-268.
29. Virchow R. Aetiologie der neoplastischen Geschwulste/Pathogenie der neoplastischen Geschwulste. In: Hirschwald VvA, ed. Die Krankhaften Geschwustle. Berlin, Germany; 1863:57-101.
30. Virchow R. Reizung und Reizbarkeit. Arch Pathol Anat Klin Med. 1858;14:1-63.
31. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71-78.
32. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196:254-265.
33. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159-2169.
34. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and Genetics of Haematopoietic and Lymphoid Tissues, Lyon, France: International Agency for Research on Cancer Press; 2001.
35. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. Am J Stat Assoc. 1958; 53:457-481.
36. Cox DR. Regression models and life tables. J R Stat Soc. 1972;B34:187.
37. Matolcsy A, Schattner EJ, Knowles DM, Casali P. Clonal evolution of B cells in transformation from low-to high-grade lymphoma. Eur J Immunol. 1999;29:1253-1264.
38. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164:6166-6173.
39. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549-555.
40. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137-148.